

Index

- Abatron Ltd 3.11
- Advertising costs 3.98
- Alcon Laboratories (UK) Ltd 3.6
 - financial results 4.28-4.34
 - views 6.191-6.204
- Allergan Ltd 3.4
 - discounts 4.88-4.89
 - financial results 4.3-4.17, App 4.2
 - monopoly situation 8.128-8.152
 - views 6.1-6.113
 - competition 6.35-6.41
 - discounts 6.74-6.89
 - market risks 6.16-6.28
 - packaging and labelling of solutions 6.101-6.103
 - prices 6.63-6.68
 - profitability 6.42-6.62
 - RRP 6.105-6.108
- Aspect Vision Care Ltd 3.11
 - views 6.253-6.259
- Association of British Dispensing Opticians
 - views 7.97-7.100
- Association of Optometrists
 - views 7.93-7.96
- Bausch & Lomb UK Ltd 3.8
 - financial results 4.35-4.43
 - views 6.205-6.221
- Boots Company PLC
 - monopoly situation 8.168-8.191
 - views 7.2-7.43
 - Boots' own-label CLS 7.21-7.26
 - opticians' recommendations 7.35-7.43
 - pricing 7.27-7.31
- Boots Opticians Ltd, financial results 4.76-4.78
- Boots The Chemists Ltd, financial results 4.65-4.75, App 4.3
- Bowden & Lowe
 - views 7.104
- British College of Optometrists
 - Code of Ethics and Guidelines 2.50-2.53, 8.13, App 2.5
 - views 7.80-7.84
- Buckley, Mr
 - views 5.48-5.49, 5.51-5.53
- CCL Industries Ltd 3.10, 3.11
- Chlorine tablets 2.16, 3.24
- CIBA Vision Lens Care Production Ltd 3.5
- CIBA Vision (UK) Ltd 3.5, 3.11
 - financial results 4.18-4.27, App 4.2
 - Macclesfield plant 3.16, 4.18
 - monopoly situation 8.153-8.167
 - views 6.114-6.190
 - discounts 6.143-6.156
 - market shares 6.123-6.131
 - packaging and labelling 6.163-6.175
 - pricing 6.122, 6.132-6.137
 - RRP 6.179-6.187
- Cold chemical solutions 2.16, 3.25
- College of Pharmacy Practice
 - views 7.121-7.122
- Committee on Dental and Surgical Materials 2.23, 2.25-2.27, 2.29
 - working party on distribution of CLS 2.27
- Committee on Safety of Medicines 2.23
- Company Chemists' Association, views 7.123-7.126
- Complex care systems
 - views of suppliers 3.33-3.36, 3.96, 6.96-6.99, 6.138-6.142, 8.72, App 3.4
- Complex monopoly situations 8.52-8.97
- Consumers
 - views 5.60-5.66
 - survey App 3.10
- Consumers' Association, views 5.39-5.47
- Contact lens solutions 2.11-2.13, App 2.6, App 3.1
 - advertising of 2.34, 3.39
 - compatibility between solutions of different brands 2.76-2.85
 - discard dates 3.28-3.30, App 3.2
 - distribution channels 2.26-2.27
 - EC legislation 2.36-2.42
 - functions 2.13, 8.4
 - future developments 2.86
 - imports 3.17
 - labelling 2.33
 - licensing system 2.24-2.25, 2.28, 2.31-2.32, 2.35, 3.83-3.92, 8.7
 - guidance notes for applicants App 2.3
 - suppliers' views 6.3, 6.27-6.28, 6.188-6.190, 6.193-6.194, 6.206-6.209, 6.223, 6.232, 6.242
 - manufacturing methods 3.18-3.19
 - market for 3.1-3.2, 3.40-3.53, 8.17-8.27, 8.98-8.114
 - market shares 3.12-3.14, 3.56-3.75, 8.18, 8.25
 - pack sizes available App 3.3
 - pricing 3.177-3.187
 - sold overseas but not in UK App 3.5
 - sources of supply 3.15-3.17
 - statutory regulation 2.19-2.24
- Contact lenses 2.1
 - cleaning of 2.11, 2.13, 2.71-2.75
 - correction of sight defects 2.8
 - costs of wearing 2.68, 3.191-3.195
 - disposable 2.9-2.10, 2.87
 - extended wear 2.9-2.10, 2.74
 - future developments 2.87-2.88
 - hard lenses 2.2
 - market for 2.60-2.64, 8.14
 - oxygen permeability 2.4
 - sales 2.7
 - soft lenses 2.3
 - wearers, survey App 3.10
 - wearing patterns 2.9
- Contact lenses, rigid gas-permeable 2.6
- Containers
 - pricing 3.197-3.198
 - sizes 3.31-3.32, 5.27, 5.44, 5.60, 8.61-8.62
- Core Technologies Ltd 3.11
- Department of Health (*see* Medicines Control Agency)
- Discard dates 3.28-3.30
- Discounts
 - by suppliers 3.97, 3.216-3.224, App 3.12

- Discounts, by suppliers—*contd*
 - retrospective 3.227-3.230
 - to consumers 3.199-3.200
 - to optical wholesalers, reduction 3.132-3.134
 - to trade channels
 - Alcon Ltd 4.92-4.93
 - Allergan Ltd 4.88-4.89
 - Bausch & Lomb UK Ltd 4.94-4.97
 - CV UK Ltd 4.90-4.91
- Disinfectant systems 2.16, 8.5
- Disinfectants 3.22-3.25
 - market shares 3.60-3.67
 - pricing 3.181-3.182
 - comparisons 3.189-3.195
- Distribution 3.99-3.112
- Dollond & Aitchison Group plc
 - financial results 4.79-4.84
 - One-2-One lens care systems 2.77
 - views 7.44-7.61
- EC, legislation (*see* EC Directive on Medical Devices)
- EC Directive on Medical Devices 2.36-2.42, 8.9, 8.217-8.218, App 2.4
- Efron, Professor N, views 5.57
- Eye surgery, possible effects of future development 2.88
- Federation of Independent British Optometrists 7.101-7.103
- Federation of Ophthalmic and Dispensing Opticians views 7.85-7.92
- Financial results
 - Alcon Laboratories (UK) Ltd 4.28-4.34
 - Allergan Ltd 4.3-4.17, App 4.2
 - Bausch & Lomb UK Ltd 4.35-4.43
 - Boots Opticians Ltd 4.76-4.78
 - Boots The Chemists Ltd 4.65-4.75, App 4.3
 - CIBA Vision (UK) Ltd 4.18-4.27, App 4.2
 - Dollond & Aitchison Group plc 4.79-4.84
 - Kelvin Optical Supplies 4.55-4.58
 - Lloyds Chemists plc 4.85-4.87
 - Madden & Layman Ltd 4.36-4.43
 - Martin Optical 4.63-4.64
 - Mid-Optic Ltd 4.59-4.62
 - Pilkington Barnes-Hind Ltd 4.51
 - Sauflon Pharmaceuticals Ltd 4.44-4.50
 - Smith & Nephew Pharmaceuticals Ltd 4.52
 - suppliers, summary of App 4.1
- General Optical Council, views 7.76-7.79
- Hydrogels 2.3
- Kelvin Optical Supplies, financial results 4.55-4.58
- Labelling, regulation of 2.33, 8.8, App 2.1
- Licensing system (*see* under Contact lens solutions)
- Lloyds Chemists plc
 - financial results 4.85-4.87
 - views 7.127-7.129
- Madden & Layman Ltd 3.8, 4.36
 - financial results 4.36-4.43
- Margins on CLS 4.100-4.103
- Market entry 3.76-3.77
 - barriers to 3.82-3.98
- Market shares of suppliers 3.56-3.75
- Markets, measurement and definition of 3.40-3.53, 8.17-8.23
- Martin Optical
 - financial results 4.63-4.64
 - views 7.131-7.132
- Meakin, B J, views 5.54-5.56
- Medicines Act 1968, extended to include contact lens solutions 2.19-2.22, 8.7
- Medicines Control Agency
 - functions 2.20, 2.23, 2.28-2.30, 8.7-8.8
 - guidance notes for applicants 2.35
 - regulations, effect on market 8.115-8.126
 - views 5.4-5.38
 - licensing requirements 3.90-3.92, App 2.3
- Medicines (Specified Articles and Substances) Order 2.24
- Medicines (Contact Lens Fluids and Other Substances) (Advertising and Miscellaneous Amendments) Regulations 1979 2.34, App 2.2
- Medicines (Contact Lens Fluids and Other Substances) (Labelling) Regulations 1979 2.33, App 2.1
- Mid-Optic Ltd
 - financial results 4.59-4.62
 - views 7.133-7.135
- Monopolies and Mergers Commission
 - conclusions, summary of 8.208-8.212
 - provisional findings App 8.1
 - questions in reference answered App 1.1
 - recommendations 8.213-8.236
 - reference 1.1, App 1.1
- Monopoly situations 8.28-8.97
- National Pharmaceutical Association
 - views 7.117-7.120
- Optical Information Council, views 5.58
- Optical practitioners
 - code of practice 2.50-2.53
 - recommendations to patients 2.65-2.67
- Opticians 3.136-3.148
 - complex monopoly situations 8.204-8.207
 - professional conduct 2.49-2.53
 - role 2.43, 2.47-2.48, 8.10-8.11
 - survey App 3.7, App 3.8
 - views 7.2-7.104
- Optometrists, role of 2.45
- Own-label solutions 3.113-3.126, 8.106
 - pricing 3.206-3.215
- Oxidatives 3.23-3.24
 - market 3.63-3.65
- Pack sizes (*see* Containers)
- Patents 3.94-3.95
- Peroxides 3.23
 - market 3.64-3.65
- Pharmaceutical Society of Northern Ireland
 - views 7.116
- Pharmacies, number 3.171
 - survey App 3.9
- Pharmacists 3.149-3.155
 - role 2.54-2.59, 8.12

Pharmacists—*contd*
 views 7.105-7.129

Pharmacopoeias 2.42

Pilkington Barnes-Hind Ltd 3.10, 3.11
 financial results 4.51
 views 6.222-6.230

Pricing
 of solutions 3.177-3.231
 international comparisons 3.188
 mark-ups 3.225-3.226
 recommended retail, 3.201-3.205, App 3.11

Product innovation 3.78-3.81

Protein cleaners 3.27
 market 3.70-3.72, 6.69-6.73
 views, Allergan Ltd 6.69-6.73
 pricing 3.185-3.186

Public interest issues 8.127-8.207

Research and development 3.98

Retail outlets selling solutions 2.26-2.27
 extension of 8.219-8.225
 number 3.156-3.158
 sales by type 3.167-3.169
 views of MCA 5.12-5.18

Retail value, CLS 3.159-3.166

Retailer power, views, Allergan Ltd 6.23-6.26

Retailers
 complex monopoly situation 8.198-8.203
 survey App 3.7, App 3.8, App 3.9

Royal Pharmaceutical Society, views 7.105-7.115

Salines 3.26
 market 3.68-3.69
 pricing 3.183-3.184
 comparisons 3.189-3.191

Sauflon Pharmaceuticals Ltd 3.7
 Ashford plant 3.16
 financial results 4.44-4.50
 views 6.231-6.240

Scale monopoly situations 8.30-8.51
 suppliers' views 6.29-6.99, 6.114-6.161

Smith & Nephew Pharmaceuticals Ltd 3.9
 financial results 4.52
 views 6.241-6.252

Socialist Health Association, views 5.59

Specsavers Optical Group Ltd 3.11
 views 7.62-7.71

Stapleton, Dr, views 5.50-5.53

Starter packs 3.37-3.38, 6.90-6.92, 6.157-6.161

Steripak Ltd 3.11

Superdrug Stores Plc, views 5.67-5.76

Supermarket, views of a 5.77-5.78

Suppliers, complex monopoly situation 8.192-8.197

Surfactant cleaners 2.82, 3.21
 market shares 3.57-3.59
 pricing 3.179-3.180

University of Bath, study of antimicrobial effectiveness of lens solutions 2.19

Vision Express Ltd, views 7.72-7.75

Waverley Pharmaceutical Ltd 3.10, 3.11
 views 6.260-6.261

Wholesale distributors 3.127-3.130
 survey App 3.6
 views 7.130-7.135